Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 33	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 34	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:30:39 ON 11 JUN 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:30:52 ON 11 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUN 2007 HIGHEST RN 936909-28-3
DICTIONARY FILE UPDATES: 10 JUN 2007 HIGHEST RN 936909-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10539522b.str





chain nodes :
11 13 14 15 16 17 18 19 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7
chain bonds :
1-11 2-22 2-23 3-21 4-13 5-20 6-18 6-19 13-14 13-24 14-15 14-16 14-17
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 5-6 5-7
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 3-7 4-5 4-13 5-6 5-7 13-24
exact bonds :
2-22 2-23 3-21 5-20 6-18 6-19 13-14 14-15 14-16 14-17
isolated ring systems :
containing 1 :

G1:C,O,S

G2:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 11:CLASS 13:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S
G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:31:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 602 TO ITERATE

100.0% PROCESSED 602 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10568 TO 13512
PROJECTED ANSWERS: 736 TO 1664

L2 50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:31:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11446 TO ITERATE

100.0% PROCESSED 11446 ITERATIONS 1336 ANSWERS
SEARCH TIME: 00.00.01

L3 1336 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'CAPLUS' ENTERED AT 14:31:50 ON 11 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Jun 2007 VOL 146 ISS 25
FILE LAST UPDATED: 10 Jun 2007 (20070610/ED)


```
=> s l3 full
L4          217 L3

=> s l4 and py<2002
      21897371 PY<2002
L5          177 L4 AND PY<2002

=> d ibib abs hitstr 1-10

L5   ANSWER 1 OF 177  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:284138  CAPLUS
DOCUMENT NUMBER:          142:355256
TITLE:                    Preparation of tricyclic-substituted piperidinols and
                          analogs as chemokine receptor antagonists
INVENTOR(S):              Luly, Jay R.; Nakasato, Yoshisuke; Ohshima, Etsuo;
                          Harriman, Geraldine C. B.; Carson, Kenneth G.; Ghosh,
                          Shomir; Elder, Amy M.; Mattia, Karen M.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S.
                          Ser. No. 989,086, abandoned.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   7
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2005070549         A1    20050331    US 2004-487168           20041007
     US 7186729            B2    20070306
     US 6613905            B1    20030902    US 1998-148823           19980904
     US 6329385            B1    20011211    US 1999-235102           19990121 <--
     US 2002119973         A1    20020829    US 1999-362837           19990728
     US 6509346            B2    20030121
     US 2002169155         A1    20021114    US 2001-989086           20011121
     WO 2003045942         A2    20030605    WO 2002-US36953          20021113
     WO 2003045942         A3    20030912
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
```

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2007060592	A1	20070315	US 2006-595653	20061110
AU 2007200261	A1	20070208	AU 2007-200261	20070123
PRIORITY APPLN. INFO.:			US 1998-148823	A2 19980904
			US 1999-235102	A2 19990121
			US 1999-362837	A2 19990728
			US 2000-627886	B2 20000728
			US 2001-989086	B2 20011121
			WO 2002-US36953	W 20021113
			US 1998-10320	B2 19980121
			AU 2002-352772	A3 20021113
			US 2004-487168	A1 20041007

OTHER SOURCE(S): MARPAT 142:355256

GI



I



II



III

AB Therapeutically effective compds. I [Z = (un)substituted heterocyclic ring fused to one or more carbocyclic aromatic rings; n = 1-4; M = NR2, CR1R2; R1 = H, OH, N3, etc.; R2 = OH, halo, acyl, aryl, etc.; R70, R71 = H, OH, N3, etc.; R72, R73 = O, N2, halo, etc.] and II [Z, n are defined as above; R2 = OH, halo, acyl, aryl, etc.] were prepared for treatment of diseases associated with aberrant leukocyte recruitment and/or activation (no data). I and II displayed chemokine binding activities with IC50 values ranging from < 1 μM to < 1000 μM. Thus, the [([1]benzoxepino[2,3-b]pyridinylidene)propyl]piperidinol III was prepared in three steps by reaction of 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with cyclopropylmagnesium bromide in THF, followed by ring cleavage-dehydration-bromination with HBr, and addition of 4-(4-chlorophenyl)-4-hydroxypiperidine to the bromide in DMF. Major and minor isomers were separated The pharmaceutical compns. comprising the compound I or II is disclosed.

IT 324782-01-6P, [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic piperidinols and pyrrolidines as chemokine

receptor antagonists for treatment of diseases associated with aberrant leukocyte recruitment and activation)

RN 324782-01-6 CAPLUS

CN [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 151 THERE ARE 151 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:869579 CAPLUS

DOCUMENT NUMBER: 137:370077

TITLE: Preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists

INVENTOR(S): Luly, Jay R.; Nakasato, Yoshisuke; Ohshima, Etsuo; Sone, Hiroki; Kotera, Osamu; Harriman, Geraldine C. B.; Carson, Kenneth G.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 138 pp., Cont.-in-part of U. S. Ser. No. 627,886.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2002169155	A1	20021114	US 2001-989086	20011121	
US 6613905	B1	20030902	US 1998-148823	19980904	
US 6329385	B1	20011211	US 1999-235102	19990121	<--
US 2002119973	A1	20020829	US 1999-362837	19990728	
US 6509346	B2	20030121			
CA 2467672	A1	20030605	CA 2002-2467672	20021113	
WO 2003045942	A2	20030605	WO 2002-US36953	20021113	
WO 2003045942	A3	20030912			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2002352772	A1	20030610	AU 2002-352772	20021113
BR	2002013633	A	20040824	BR 2002-13633	20021113
EP	1448566	A2	20040825	EP 2002-789725	20021113
EP	1448566	B1	20060315		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN	1585772	A	20050223	CN 2002-827426	20021113
JP	2005510565	T	20050421	JP 2003-547392	20021113
HU	200500079	A2	20050428	HU 2005-79	20021113
AT	320431	T	20060415	AT 2002-789725	20021113
EP	1688418	A2	20060809	EP 2006-4401	20021113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PT	1448566	T	20060831	PT 2002-789725	20021113
ES	2260497	T3	20061101	ES 2002-2789725	20021113
CN	1911930	A	20070214	CN 2006-10105450	20021113
IN	2004DN01154	A	20050401	IN 2004-DN1154	20040429
ZA	2004003530	A	20050728	ZA 2004-3530	20040510
NO	2004002500	A	20040615	NO 2004-2500	20040615
HK	1063789	A1	20060811	HK 2004-106595	20040902
US	2005070549	A1	20050331	US 2004-487168	20041007
US	7186729	B2	20070306		
US	2007060592	A1	20070315	US 2006-595653	20061110
AU	2007200261	A1	20070208	AU 2007-200261	20070123

PRIORITY APPLN. INFO.:

US 1998-148823	A2	19980904
US 1999-235102	A2	19990121
US 1999-362837	A2	19990728
US 2000-627886	A2	20000728
US 1998-10320	B2	19980121
US 2001-989086	A	20011121
AU 2002-352772	A3	20021113
CN 2002-827426	A3	20021113
EP 2002-789725	A3	20021113
WO 2002-US36953	W	20021113
US 2004-487168	A1	20041007

OTHER SOURCE(S): MARPAT 137:370077

GI



I II

AB Therapeutically effective compds. I [Z = (un)substituted cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings; n = 1-4; M = NR2, CR1R2, OCR1R2O, CH2CR1R2O; R1 = H, OH, N3, etc.; R2 = H, acyl, aryl, etc.; q1 = 0-3; q2 = 0-1; ring containing M is substituted or unsubstituted; and physiol. acceptable salts thereof] were prepared for treatment of diseases associated with aberrant leukocyte recruitment and/or activation (no data). I displayed chemokine binding activities with IC50 values ranging from < 1 μM to < 1000 μM. Thus, the

[([1]benzoxepino[2,3-b]pyridinylidene)propyl]piperidinol II was prepared in three steps by reaction of 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with cyclopropylmagnesium bromide in THF, followed by ring cleavage-dehydration-bromination with HBr, and addition of 4-(4-chlorophenyl)-4-hydroxypiperidine to the bromide in DMF. Major and minor isomers were separated

IT 324782-01-6P, [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic piperidinols as chemokine receptor antagonists for treatment of diseases associated with aberrant leukocyte recruitment and activation)

RN 324782-01-6 CAPLUS

CN [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:658747 CAPLUS

DOCUMENT NUMBER: 137:185480

TITLE: Preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists

INVENTOR(S): Luly, Jay R.; Nakasato, Yoshisuke; Ohshima, Etsuo; Sone, Hiroki; Kotera, Osamu; Harriman, Geraldine C. B.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 102 pp., Cont.-in-part of U.S. Ser. No. 235,102.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 2002119973	A1	20020829	US 1999-362837	19990728	
US 6509346	B2	20030121			
US 6613905	B1	20030902	US 1998-148823	19980904	
US 6329385	B1	20011211	US 1999-235102	19990121	<--
CA 2391267	A1	20010208	CA 2000-2391267	20000728	<--
WO 2001009138	A2	20010208	WO 2000-US20732	20000728	<--
WO 2001009138	A3	20010913			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1204665	A2	20020515	EP 2000-950880	20000728

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

BR 2000013065	A	20020730	BR 2000-13065	20000728
HU 200202202	A2	20021128	HU 2002-2202	20000728
JP 2003506377	T	20030218	JP 2001-514341	20000728
US 2002169155	A1	20021114	US 2001-989086	20011121
US 2003045516	A1	20030306	US 2002-217865	20020813
WO 2003045942	A2	20030605	WO 2002-US36953	20021113
WO 2003045942	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

HU 200500079	A2	20050428	HU 2005-79	20021113
US 2005070549	A1	20050331	US 2004-487168	20041007
US 7186729	B2	20070306		
AU 2007200261	A1	20070208	AU 2007-200261	20070123

PRIORITY APPLN. INFO.:	US 1998-10320	B2 19980121
	US 1998-148823	A2 19980904
	US 1999-235102	A2 19990121
	US 1999-362837	A 19990728
	US 2000-627886	A2 20000728
	WO 2000-US20732	W 20000728
	US 2001-989086	A2 20011121
	AU 2002-352772	A3 20021113
	WO 2002-US36953	W 20021113

OTHER SOURCE(S): MARPAT 137:185480

GI



I



II

AB Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Therapeutically effective tricyclic-substituted piperidinols and analogs thereof, represented by structural formula I [M = CR1R2 where R1 = H, OH, alkyl, (un)substituted alkoxy, SR3; R3 = H or substituted alkyl, (un)substituted alkylcarboxy, alkoxycarbonyl, CN, COOH, CONR4R5; R2 = OH, (un)substituted acyl, NR6R7, (un)substituted alkyl, aryl, etc.; R4-7 = H, (un)substituted acyl, aliphatic aromatic, heterocycle, etc., or, R1, R2, R4 and R5, or R6 and R7 taken together with the atom to which they are bonded form a (un)substituted carbocyclic or heterocyclic ring; Z = (un)substituted cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings; n = 1-4] and their physiol. acceptable salts are prepared Chemokine binding activities of test compds. are reported with IC50 values ranging from <1 to <1000 μM. Thus, II was prepared via substitution of 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 4-(4-chlorophenyl)-4-hydroxypiperidine.

IT 324782-01-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists for treatment of diseases associated with aberrant leukocyte recruitment and activation)

RN 324782-01-6 CAPLUS

CN [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:462644 CAPLUS
DOCUMENT NUMBER: 137:6174
TITLE: Azabicycloalkyl esters and amides of 2-oxo-2,3-dihydrobenzimidazole-1-carboxylic acid and their preparation, pharmaceutical compositions, and use as 5-HT4 receptor agonists
INVENTOR(S): Pellegrini, Carlo Maria; Cereda, Enzo; Ezhaya, Antoine; Schiavi, Giovanni Battista; Sagrata, Angelo; Giraldo, Ettore
PATENT ASSIGNEE(S): Boehringer Ingelheim Italia S.p.A., Italy
SOURCE: Ital., 62 pp.
CODEN: ITXXBY
DOCUMENT TYPE: Patent
LANGUAGE: Italian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IT 1298271	B1	19991220	IT 1998-MI305	19980218 <--
PRIORITY APPLN. INFO.:			IT 1998-MI305	19980218

OTHER SOURCE(S): MARPAT 137:6174
GI



I



II

AB Title compds. I are disclosed [wherein: R = H, Me; Y = O, NH; Z = CH2, bond; n = 0, 1, 2, 3, except that when R1 = H, then n ≠ 0 or 1; R1 = H, iso-Pr, Et, iso-Bu, cyclopropyl, cyclobutyl, cyclohexyl, vinyl, 2-methylpropenyl, 1-hydroxyethyl, ethynyl, benzyl, CONH2, CONMe2, COCH3, cyano, OR2, SR2, NR3R4; R2 = H, C1-3 alkyl; R3 = H, CH3, CONHEt, CONH2, CO2Et, COCH3, SO2Me; R4 = H, Me; including racemates, enantiomers,

diastereomers, mixts., and physiol. acceptable acid addition salts]. The compds. are serotoninergic agonists, and have a high affinity and specificity for 5-HT4 serotoninergic receptors. As such they are useful for treating a variety of cardiovascular, gastrointestinal, and CNS diseases and disorders. Over 60 compds., including both esters (Y = O) and amides (Y = NH), were prepared For instance, 1-isopropyl-2-oxo-2,3-dihydrobenzimidazole was treated with Cl3COCOCl in THF to give the 1-carbonyl chloride derivative, which reacted with endo-8-n-propyl-8-azabicyclo[3.2.1]octan-3-ol (preparation given) in CH2Cl2 to give title compound

II [Q = n-Pr], isolated as the HCl salt. The similarly prepared compound II.HCl [Q = iso-Bu] bound to porcine striatal 5-HT4 receptors in vitro with a Ki of 3.6 + 10-8 M, but bound to 5-HT3 receptors (NG 108-15 cells) with a weaker Ki of 446 + 10-8 M. Selected I also induced contractions in isolated guinea pig colon, with an efficacy comparable to 5-HT, and with blocking by the known 5-HT4 antagonist GR 113808.

IT 433226-62-1P, endo-8-n-Propyl-8-azabicyclo[3.2.1]oct-3-yl 3-isopropyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
433226-68-7P, endo-8-n-Propyl-8-azabicyclo[3.2.1]oct-3-yl 3-ethyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
433226-74-5P, endo-8-(3-Methylbutyl)-8-azabicyclo[3.2.1]oct-3-yl 3-isopropyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
433226-75-6P, endo-8-n-Butyl-8-azabicyclo[3.2.1]oct-3-yl 3-isopropyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
433227-48-6P, endo-8-n-Propyl-8-azabicyclo[3.2.1]oct-3-yl 3-ethyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of azabicycloalkyl esters and amides of oxodihydrobenzimidazolecarboxylic acid as 5-HT4 receptor agonists)

RN 433226-62-1 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-3-(1-methylethyl)-2-oxo-, (3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 433226-68-7 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 3-ethyl-2,3-dihydro-2-oxo-, (3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 433226-74-5 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-3-(1-methylethyl)-2-oxo-, (3-endo)-8-(3-methylbutyl)-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 433226-75-6 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-3-(1-methylethyl)-2-oxo-, (3-endo)-8-butyl-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 433227-48-6 CAPLUS
CN 1H-Benzimidazole-1-carboxylic acid, 3-ethyl-2,3-dihydro-2-oxo-, (3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 22226-44-4P, endo-8-Isopentyl-8-azabicyclo[3.2.1]octan-3-ol
60205-27-8P, endo-8-Propyl-8-azabicyclo[3.2.1]octan-3-ol
60205-34-7P, endo-8-Butyl-8-azabicyclo[3.2.1]octan-3-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of azabicycloalkyl esters and amides of oxodihydrobenzimidazolecarboxylic acid as 5-HT4 receptor agonists)

RN 22226-44-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-(3-methylbutyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 60205-27-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-propyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 60205-34-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-butyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 5 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:817246 CAPLUS
DOCUMENT NUMBER: 135:357843
TITLE: Preparation of 2-Aryl indole derivatives for use as tachykinin receptor antagonists
INVENTOR(S): Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Ridgill, Mark Peter; Shaw, Duncan Edward
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2001039286	A1	20011108	US 2001-782422		20010213 <--
PRIORITY APPLN. INFO.:			GB 2000-3397	A	20000214
OTHER SOURCE(S):	MARPAT 135:357843				

GI



I

AB 2-Aryl indole derivs. I (wherein R1a, R1b, and R2 = a variety of substituents; R3 = optionally substituted Ph, biphenyl or naphthyl or heteroaryl group; R4 = H, (C1-6)alkyl, carbonyl (=O), (CH2)pphenyl or a (C1-2)alkylene bridge across the piperidine ring; R5 and R6 = variety of substituents; or R5 and R6 together are linked so as to form an optionally substituted 5-or 6-membered ring; X = O or S, two H atoms, boxHNH or boxHN(C1-6 alkyl); Y = straight or branched (C1-4)alkylene, (C2-4)alkenylene or (C2-4)alkynylene chain; the dotted line represents an optional double bond; m = 0,1,2,3,4; n = 1,2,3,4; and p = 1,2,3,4), or a pharmaceutically acceptable salt thereof, were prepared, and their use as tachykinin receptor antagonists evaluated. Thus, diisopropylethylamine and bromoacetonitrile were added to a loaded resin (synthetic preparation given) in N-methylpyrrolidinone, to which was added a solution of 6-(methylsulfonyl)spiro-[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one in THF to give 1'-{3-[5-chloro-2-(4-chlorophenyl)-1H-indol-3-yl]-1-oxopropyl}-6-(methylsulfonyl)spiro(2H-1-benzopyran-2,4'-piperidin)-4(3H)-one. The compds. are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. Biol. data are given.

IT 371970-31-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl indole derivs. as tachykinin receptor antagonists for treatment for)

RN 371970-31-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-[5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indol-3-yl]propyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:785490 CAPLUS
DOCUMENT NUMBER: 136:85971
TITLE: Novel tropane-based irreversible ligands for the dopamine transporter
AUTHOR(S): Zou, Mu-Fa; Kopajtic, Theresa; Katz, Jonathan L.; Wirtz, Sara; Justice, Joseph B., Jr.; Newman, Amy Hauck
CORPORATE SOURCE: Medicinal Chemistry and Psychobiology Sections, National Institute on Drug Abuse-Intramural Research Program, Baltimore, MD, 21131, USA
SOURCE: Journal of Medicinal Chemistry (2001), 44(25), 4453-4461
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:85971

AB 3α-(Diphenylmethoxy)tropane (benztropine) and its analogs are tropane ring-containing dopamine uptake inhibitors that display binding and behavioral profiles that are distinct from cocaine. The authors previously prepared a benztropine-based photoaffinity label [125I]-N-[4-(4'-azido-3'-iodophenyl)butyl]-3α-[bis(4'-fluorophenyl)methoxy]tropane, (I), that covalently attached to the 1-2 transmembrane spanning region of the dopamine transporter (DAT). This was in contrast to the 4-7 transmembrane spanning region labeled by a cocaine-based photoaffinity label, (RTI 82) (II). To characterize further these different binding domains, photoaffinity ligands that had the 4'-azido-3'-iodophenyl substituent extended from the same position on the tropane ring were desirable. Thus, identification of the optimal alkyl linker between this substituent and the tropane nitrogen in the benztropine series was investigated to ultimately prepare the identical N-substituted analog of II. In this pursuit, the N-[4-(4'-azido-3'-iodophenyl)propyl] analog of 3α-[bis(4'-fluorophenyl)methoxy]tropane was synthesized as well as two isothiocyanate analogs that do not require photoactivation for irreversible binding. The synthesis of these target compds. was achieved using a modification of the strategy developed for I. Evaluation of these compds. for displacing [3H]WIN 35 428 binding at DAT in rat caudate putamen revealed that the 4'-azido-3'-iodophenylbutyl substituent, found in I, provided optimal binding affinity and was chosen to replace the N-CH3 group on II. Both the 4'-azido-3'-iodophenyl- and the 4'-isothiocyanatophenylbutyl analogs of II were synthesized. Both products bound to DAT with comparable potency (IC50 = 30 nM) to RTI 82. In addition, the 4'-isothiocyanatophenylbutyl analog of II demonstrated wash-resistant displacement of [3H]WIN 35 428 in HEK 293 cells stably transfected with hDAT. These ligands will provide important tools for further characterizing the binding domains for tropane-based dopamine uptake inhibitors at the DAT.

IT 387357-10-0P 387357-11-1P 387357-19-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and dopamine transporter binding of tropane-based irreversible ligands with interest in developing cocaine abuse treatment)

RN 387357-10-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-(4-azido-3-iodophenyl)propyl]-3-[bis(4-fluorophenyl)methoxy]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 387357-11-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-[3-(4-isothiocyanatophenyl)propyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 387357-19-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-[4-(4-isothiocyanatophenyl)butyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 203048-97-9P 387357-08-6P 387357-09-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dopamine transporter binding of tropane-based irreversible ligands with interest in developing cocaine abuse treatment)

RN 203048-97-9 CAPLUS
CN Benzenamine, 4-[4-[(3-endo)-3-[bis(4-fluorophenyl)methoxy]-8-azabicyclo[3.2.1]oct-8-yl]butyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 387357-08-6 CAPLUS
CN Benzenamine, 4-[3-[(3-endo)-3-[bis(4-fluorophenyl)methoxy]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 387357-09-7 CAPLUS
CN Benzenamine, 4-[3-[(3-endo)-3-[bis(4-fluorophenyl)methoxy]-8-azabicyclo[3.2.1]oct-8-yl]propyl]-2-iodo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 387357-17-7P 387357-18-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dopamine transporter binding of tropane-based irreversible ligands with interest in developing cocaine abuse treatment)
RN 387357-17-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-(4-azido-3-iodophenyl)propyl]-3-[bis(4-fluorophenyl)methoxy]-, (3-endo)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 387357-10-0
CMF C29 H29 F2 I N4 O

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 387357-18-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-[3-(4-isothiocyanatophenyl)propyl]-, monohydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:749720 CAPLUS
DOCUMENT NUMBER: 136:37802
TITLE: Synthesis and biological evaluation of tropane-like

1-{2-[bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909) analogs

AUTHOR(S): Zhang, Ying; Joseph, David B.; Bowen, Wayne D.; Flippen-Anderson, Judith L.; Dersch, Christina M.; Rothman, Richard B.; Jacobson, Arthur E.; Rice, Kenner C.

CORPORATE SOURCE: Laboratory of Medicinal Chemistry National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892-0815, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(23), 3937-3945
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:37802

AB The authors have prepared azabicyclo[3.2.1] derivs. (C-3-substituted tropanes) that bind with high affinity to the dopamine transporter and inhibit dopamine reuptake. Within the series, 3-{2-[bis-(4-fluorophenyl)methoxy]ethylidene}-8-methyl-8-azabicyclo[3.2.1]octane (I) was found to have the highest affinity and selectivity for the dopamine transporter. These azabicyclo[3.2.1] (bridged piperidine) series of compds. differ from the well-known benztropines by a 2-carbon spacer between C-3 and a diarylmethoxy moiety. Interestingly, these new compds. demonstrated a much lower affinity for the muscarinic-1 site, at least a 100-fold decrease compared to benztropine. Interestingly, these new compds. demonstrated a much lower affinity for the muscarinic-1 site, at least a 100-fold decrease compared to benztropine. Replacing N-Me with N-phenylpropyl in two of the compds. resulted in a 3-10-fold increase in binding affinity for the dopamine transporter. However, those compds. lost selectivity for the dopamine transporter over the serotonin transporter. Replacement of the ether oxygen in the diarylmethoxy moiety with a nitrogen atom gave relatively inactive amines, indicating the important role which is played by the ether oxygen in transporter binding. Reduction of the C-3 double bond in I gave 3α-substituted tropanes, as shown by X-ray crystallog. analyses. The 3α-substituted tropanes had lower affinity and less selectivity than the comparable unsatd. ligands.

IT 380602-02-8P 380602-03-9P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, muscarinic M1 receptor, dopamine and serotonin transporter affinity, and structure-activity relationship of azabicyclooctane derivs. as GBR 12909 analogs)

RN 380602-02-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[2-(diphenylmethoxy)ethyl]-8-(3-phenylpropyl)-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 380602-03-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-8-(3-phenylpropyl)-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:574757 CAPLUS
DOCUMENT NUMBER: 135:303847
TITLE: Design and Synthesis of [(2,3-Dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as Novel Ligands Selective for the Dopamine D3 Receptor Subtype
AUTHOR(S): Robarge, Michael J.; Husbands, Stephen M.; Kieltyka, Andrzej; Brodbeck, Robbin; Thurkauf, Andrew; Newman, Amy Hauck
CORPORATE SOURCE: Medicinal Chemistry Section, National Institute on Drug Abuse-Intramural Research Program, Baltimore, MD, 21224, USA
SOURCE: Journal of Medicinal Chemistry (2001), 44(19), 3175-3186
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:303847
GI



I

AB The dopamine D3 receptor subtype has been recently targeted as a potential neurochem. modulator of the behavioral actions of psychomotor stimulants, such as cocaine. However, definitive behavioral investigations have been hampered by the lack of highly selective D3 agonists and antagonists. In

an attempt to design a novel class of D3 ligands with which to study this receptor system, a series of chemical divergent compds. that possessed various structural features that exist within several classes of reputed D3 agents was screened and compared to the recently reported NGB 2904. On the basis of these results, a novel series of compds. was designed that included functional moieties that were required for high-affinity and selective binding to D3 receptors. All the compds. in this series included an aryl-substituted piperazine ring, a varying alkyl chain linker (C3-C5), and a terminal aryl amide. The compds. were synthesized and evaluated in vitro for binding in CHO cells transfected with human D2, D3, or D4 receptor cDNAs. D3 binding affinities ranged from Ki = 1.4 to 1460 nM. The most potent analog in this series, I, demonstrated a D3/D2 selectivity of 64 and a D3/D4 selectivity of 1300. Structure-activity relationships for this class of ligands at D3 receptors will provide new leads toward the development of highly selective and potent mol. probes that will prove useful in the elucidation of the role D3 receptors play in the psychomotor stimulant and reinforcing properties of cocaine.

IT 264869-03-6 367275-32-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as ligands selective for the dopamine D3 receptor)

RN 264869-03-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-(4-phenylbutyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 367275-32-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[(3-chlorophenyl)phenylmethoxy]-8-(3-phenylpropyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:560064 CAPLUS

DOCUMENT NUMBER: 135:137519
TITLE: Preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists
INVENTOR(S): Nagarathnam, Dhanapalan; Chiu, George; Dhar, T. G. Murali; Wong, Wai C.; Marzabadi, Mohammad R.; Gluchowski, Charles; Lagu, Bharat; Miao, Shou Wu
PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corp., USA
SOURCE: U.S., 67 pp., Cont.-in-part of U. S. Ser. No. 340,611, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6268369	B1	20010731	US 1997-836628	19970516 <--
WO 9614846	A1	19960523	WO 1995-US15025	19951116 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6248747	B1	20010619	US 1999-291553	19990414 <--
US 6727257	B1	20040427	US 2000-730458	20001205

PRIORITY APPLN. INFO.:

US 1994-340611	B2	19941116
WO 1995-US15025	W	19951116
US 1997-836628	A1	19970516
US 1997-978682	A3	19971126

OTHER SOURCE(S): MARPAT 135:137519
GI



I



II

AB Title compds. [e.g., I; R = (un)substituted (hetero)aryl; R1 = H, (fluoro)alkyl, cyano, CO2R3, etc.; R2 = H, alkyl, OR3, etc.; R3 = H, (fluoro)alkyl, etc.; R4 = e.g, (4-arylpiperidinopropyl)carbamoyl; X = O,

S, (alkyl)imino] and analogs thereof were prepared Over 60 synthetic examples were provided. Thus 1,6-dihydro-5-(cyanoethoxycarbonyl)-4-ethyl-6-(4-nitrophenyl)-2-methoxypyrimidine (prepared in 3 steps) was treated with 4-nitrophenylchloroformate (acylation at N1) followed by the corresponding substituted piperidine to give the N1 carboxamide intermediate. The cyanoethoxycarbonyl function was saponified and converted to the 5-carboxamido derivative II. Thus, title compound II had pKi of 9.74 for binding at human α1c receptors in vitro. Treatment of benign prostatic hyperplasia is a claimed use of the invention.

IT 179481-64-2P 179481-65-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α1c antagonists)

RN 179481-64-2 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-1-[[[3-(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]amino]carbonyl]-4-methyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 179481-65-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-1-[[[3-(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]amino]carbonyl]-4-methyl-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:338355 CAPLUS
DOCUMENT NUMBER: 134:340509
TITLE: Preparation of 8-azabicyclo[3.2.1]octane NMDA/NR2B antagonists
INVENTOR(S): Thompson, Wayne; Claremon, David A.; Munson, Peter M.; Phillips, Brian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032179	A1	20010510	WO 2000-US29479	20001026 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6432976	B1	20020813	US 2000-696503	20001025
CA 2388171	A1	20010510	CA 2000-2388171	20001026 <--
EP 1244450	A1	20021002	EP 2000-979131	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003513044	T	20030408	JP 2001-534384	20001026

PRIORITY APPLN. INFO.: US 1999-162718P P 19991029
WO 2000-US29479 W 20001026

OTHER SOURCE(S): MARPAT 134:340509
GI



I



II

AB The title compds., commonly known as tropanes, (I) [wherein R1 = (un)substituted 2-benzimidazole, imidazole, imidazopyridine, indole, quinazoline, purine, benzoxazolone, or phenol; R2 = Ph, optionally substituted with 1-5 substituents selected from Cl, F, Br, alkyl, CF3, OH, or CO2H; L1 and L2 = independently (cyclo)alkyl, alkenyl, alkynyl, alkoxy, aminoalkyl, hydroxyalkyl, or (amino)carbonyl; X = OH, NH2, (di)alkylamino,

alkyl, ester, carbamate, carbonate, or ether] were prepared as effective NMDA NR2B glutamate receptor antagonists. For example, addition of di-Et 4-chlorobenzylphosphonate to N-carbethoxy-4-tropinone to give the benzylidene, reduction using Pt/C, N-deprotection using HBr in AcOH, and reductive addition of 1-(trimethylsilylethoxymethyl)-1H-benzimidazole-2-carbaldehyde (2-step preparation given) using NaBH(OAc)3 in ClCH2CH2Cl afforded exo-II. Exptl. protocols for assessing the inhibition of NR1A/2B NMDA receptor activation (FLIPR assay) and determining the apparent dissociation consts.
against the human NR1A/NR2B receptor (binding assay) are given (no data). I are useful for relieving pain and treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke (no data).

IT 338733-30-5P 338733-34-9P 338733-35-0P
338733-37-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (benzimidazolylalkyl)tropane NMDA/NR2B antagonists for treatment of pain)

RN 338733-30-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-[4-(phenylmethoxy)phenyl]propyl]-3-(phenylmethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338733-34-9 CAPLUS
CN 1H-Benzimidazole-1-propanenitrile, 2-[3-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 338733-35-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-butanoic acid, 3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 338733-37-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-butanoic acid, 3-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 338732-79-9P 338732-81-3P 338732-86-8P
338732-89-1P 338732-91-5P 338732-92-6P
338733-09-8P 338733-10-1P 338733-13-4P
338733-16-7P 338795-47-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (benzimidazolylalkyl)tropane NMDA/NR2B antagonists for treatment of pain)

RN 338732-79-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-imidazol-4-yl)propyl]-3-(phenylmethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338732-81-3 CAPLUS
CN Phenol, 4-[3-[(3-exo)-3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338732-86-8 CAPLUS
CN Phenol, 4-[3-[(3-exo)-3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338732-89-1 CAPLUS
CN Phenol, 4-[3-[(3-exo)-3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]butyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338732-91-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-benzimidazol-2-yl)propyl]-3- (phenylmethyl)- (9CI) (CA INDEX NAME)



RN 338732-92-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-imidazo[4,5-b]pyridin-2-yl)propyl]-3- (phenylmethyl)- (9CI) (CA INDEX NAME)



RN 338733-09-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-imidazol-4-yl)propyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 338733-10-1 CAPLUS
CN Phenol, 4-[3-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 338733-13-4 CAPLUS
CN Phenol, 4-[3-[3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 338733-16-7 CAPLUS
CN Phenol, 4-[3-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]butyl]- (9CI) (CA INDEX NAME)



RN 338795-47-4 CAPLUS
CN Phenol, 4-[3-[(3-endo)-3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	55.65	228.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

FILE 'STNGUIDE' ENTERED AT 14:33:14 ON 11 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 8, 2007 (20070608/UP).

=> d his

(FILE 'HOME' ENTERED AT 14:30:39 ON 11 JUN 2007)

FILE 'REGISTRY' ENTERED AT 14:30:52 ON 11 JUN 2007
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 1336 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:31:50 ON 11 JUN 2007
L4 217 S L3 FULL
L5 177 S L4 AND PY<2002

FILE 'STNGUIDE' ENTERED AT 14:33:14 ON 11 JUN 2007

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	228.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.80

Connection closed by remote host